据悉，赛沃替尼用于治疗非小细胞肺癌的SACHI研究、SAVANNAH研究以及一项IIIb期验证性研究的最 新分析结果将于 2025年世界肺癌大会公布。赛沃替尼是一种强效、高选择性的口服MET酪氨酸激酶抑 制剂(TKI)，由阿斯利康与和黄医药共同开发，并由阿斯利康商业化。 智通财经APP讯，和黄医药(00013)公布，将于2025年9月6日至9日在西班牙巴塞罗那召开的2025年世界 肺癌大会(WCLC)，以及2025年9月10至14日在中国济南召开的中国临床肿瘤学会 (CSCO)2025年年会上 公布和黄医药自主研发的化合物的数项研究的最新及更新后的数据。 HMPL-653(一种新型、选择性、强效的CSF-1R抑制剂)在中国腱鞘巨细胞瘤患者中开展的首个人体I期临 床试验数据将于2025年CSCO年会上首次公布。 ...

Core Insights - HUTCHMED will present new and updated data from several studies at the 2025 World Conference on Lung Cancer (WCLC) and the Chinese Society of Clinical Oncology (CSCO) Annual Meeting [1][2][3] Group 1: WCLC Presentations - Updated analysis from savolitinib's studies, including SACHI, SAVANNAH, and a Phase IIIb confirmatory study in non-small cell lung cancer (NSCLC) patients, will be presented [2] - Specific presentations include: - "Biomarker Concordance and Acquired Resistance in Patients with EGFRm MET-OverExp and/or Amp NSCLC" by Christina Baik on September 7, 2025 [2] - "Efficacy and Safety of Savolitinib in Advanced or Metastatic METex14 NSCLC Patients With or Without Prior Immunotherapy" by Yongfeng Yu on September 9, 2025 [2] - Insights from the SACHI study regarding frontline treatment duration in MET-Amplified NSCLC after third-generation EGFR-TKI failure [2] Group 2: CSCO Annual Meeting Presentations - Clinical data of HMPL-653, a novel CSF-1R inhibitor, will be presented for the first time at the CSCO Annual Meeting [3] - Specific presentations include: - A first-in-human Phase I study of HMPL-653 in patients with tenosynovial giant cell tumor by Xiaohui Niu on September 12, 2025 [3] - Updated efficacy and safety data for Fruquintinib in various cancer types, including metastatic or unresectable non-clear cell renal cell carcinoma and advanced esophageal squamous cell carcinoma [3][4] Group 3: Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery and global development of targeted therapies and immunotherapies for cancer and immunological diseases [5] - The company has successfully marketed its first three medicines in China, with the first also approved in the US, Europe, and Japan [5]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不 對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 （於開曼群島註冊成立的有限公司） （股份代號：13） | 摘要標題 | 報告人/ 主要作者 | 報告詳情 | | --- | --- | --- | | 研究者發起的研究 | | | | 索凡替尼、度伐利尤單抗聯合化療用於一線治療廣泛期小細胞肺癌的療效及 | 張卉/ 胡瑛，北京胸科 | P3.13.22 | | 安全性 | 醫院，中國北京 | 海報展示 Poster: Small Cell Lung | | Efficacy and Safety of Surufatinib, Durvalumab in Combined with | | Cancer and Neuroendocrine | | Chemotherapy as First-line Treatment of Extensive-stage Small-cell ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 和黃醫藥（中國）有限公司 呈交日期: 2025年9月1日 II. 已發行股份及/或庫存股份變動 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00013 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,500,000,000 | USD | | 0.1 USD | | | 150,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | | | | 本月底結存 | | | 1,500,000,000 | USD | | 0.1 USD | | | 1 ...

Core Viewpoint - The announcement from Hutchison China MediTech Limited (HutchMed) regarding the temporary suspension of its CEO due to health reasons and the appointment of the CFO as acting CEO [1] Company Summary - HutchMed's board has acknowledged that the CEO, Su Weiguo, will pause his duties for health reasons [1] - The board has appointed Zheng Zefeng, the executive director and CFO, to serve as the acting CEO effective immediately [1]

Group 1 - The Shanghai Science and Technology Awards 2024 recognized a total of 206 awards, including various categories such as the Shanghai Science and Technology Progress Award and the Shanghai International Science and Technology Cooperation Award [1] - Among the award recipients, 1,171 individuals under the age of 45 accounted for 65% of the total, indicating a growing recognition of young scientists in Shanghai's innovation landscape [2] - The number of enterprises involved in award-winning projects reached 336, representing 49% of all completion units, with a notable increase in participation from private enterprises [3] Group 2 - The focus on technology transfer and industrial application is emphasized, with 34 projects directly mentioning "application," making up 54% of high-level award-winning results [4] - The Shanghai government is actively promoting the construction of an international technology innovation center, supporting both state-owned and private enterprises in innovation and development [5] - The success of young scientists and enterprises is seen as a vital source of innovation for Shanghai's technological ecosystem [6]

Group 1 - The core viewpoint of the article highlights a significant decline in innovative drug concept stocks in Hong Kong, with notable drops in companies such as Innovent Biologics (5.3% decrease), CStone Pharmaceuticals (3.72% decrease), and others [1] - U.S. President Trump's announcement to reduce drug prices to 1/1400 to 1/1500 of current prices and impose tariffs on drugs could create turbulence in the global pharmaceutical industry, presenting both opportunities and challenges for Chinese biopharmaceutical stocks [1] - Morgan Stanley's report suggests that the likelihood of tariffs on outbound licensing cooperation (BD) payments is low, as current U.S. tariffs primarily target tangible goods and focus on production repatriation, with service-related revenues, including intellectual property transfers, receiving less attention [1] Group 2 - The majority of BD agreements include granting development and manufacturing rights to global licensors, with some licensors planning to produce approved licensed drugs locally in the U.S. after receiving approval [1]

Core Viewpoint - The innovative drug concept stocks experienced a significant decline in the afternoon trading session, influenced by President Trump's announcement regarding drastic cuts in drug prices and potential tariffs on pharmaceuticals, which could create both opportunities and challenges for the global pharmaceutical industry, particularly for Chinese biotech stocks [1] Group 1: Stock Performance - Innovent Biologics (01801) fell by 5.3%, trading at HKD 94.65 [1] - Innovent Biologics (09969) decreased by 3.72%, trading at HKD 17.35 [1] - Federated Pharmaceutical (03933) dropped by 3.03%, trading at HKD 16.31 [1] - Hutchison China MediTech (00013) declined by 1.98%, trading at HKD 24.74 [1] Group 2: Regulatory Impact - President Trump stated that drug prices would be reduced to 1/1400 to 1/1500 of current prices, with immediate tariffs on pharmaceuticals [1] - Analysts suggest that if implemented, this could cause significant disruption in the global pharmaceutical industry [1] Group 3: Market Analysis - Morgan Stanley's report indicates that the likelihood of tariffs on outbound licensing deals (BD) payments is low [1] - Current U.S. tariffs primarily target tangible goods, focusing on production repatriation, while service-related revenues, including intellectual property transfers, are less affected [1] - Most BD agreements grant development and manufacturing rights to global licensees, with some licensees planning to produce approved licensed drugs locally in the U.S. after receiving approval [1]

HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 （於開曼群島註冊成立的有限公司） （股份代號：13） 董事名單及其角色與職能 和黃醫藥(中國)有限公司董事會由 9 名董事組成，載列如下： 主席兼非執行董事 施熙德女士 楊凌女士 獨立非執行董事 莫樹錦教授 （高級兼首席獨立非執行董事） Dr Renu BHATIA（言思雅醫生） Dr Chaohong HU（胡朝紅博士） 黃德偉先生 下表提供董事會成員在委員會中之職務。 | 董事委員會 | 審核委員會 | 提名委員會 | 薪酬委員會 | 可持續發展 | 技術委員會 | | --- | --- | --- | --- | --- | --- | | 董事 | | | | 委員會 | | | 艾樂德 | - | M | - | - | M | | 蘇慰國 | - | - | - | - | M | | 鄭澤鋒 | - | - | - | M | - | | 施熙德 | - | - | M | C | - | | 楊凌 | - | - | - | - | - | | 莫樹錦 | - | C | - | M | C | | 言思雅 | M ...

Core Viewpoint - The management change at Hutchison China MediTech (HCM) reflects a strategic shift from a research-driven model to a dual focus on research and commercialization, aiming to enhance the market realization of its pipeline value [5] Financial Performance - HCM reported total revenue of $277.7 million for the first half of 2023, down from $305.7 million in the same period last year [2] - The net profit attributable to HCM for the first half of 2023 was $455 million, a significant increase from $25.8 million in the previous year [2] Product Performance - Total sales of oncology products amounted to $234 million, a decline of 4% year-on-year [3] - Overseas sales of the main product, fruquintinib, reached $163 million, up 25% year-on-year, while domestic sales fell by 29% to $43 million [3] - Other oncology products, such as surufatinib and savolitinib, experienced significant declines in sales, with surufatinib down 50% and savolitinib down 41% [3] - The overall revenue from the oncology immunotherapy business decreased by 14.9% [3] Strategic Transition - HCM is at a "triple turning point," focusing on expanding market share and indications for core products, enhancing pipeline value, and implementing international strategies [4] - The management change is seen as a necessary step to support the transition from a domestic leader to an international biopharmaceutical company [5] Future Outlook - HCM plans to initiate Phase I clinical trials for new candidates in late 2025, with additional candidates expected to enter trials in 2026 [5] - The company aims to achieve a performance turning point by the second half of 2025, contingent on the approval of fruquintinib in more overseas markets and the advancement of new indications for savolitinib [5]